|
|
Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology > General
MicroRNA in Human Malignancies offers a deep overview of the role
and translational significance of miRNAs in the development of
cancer and other malignancies. The book establishes the foundations
of the field by covering essential mechanisms and the translational
potential of miRNAs in the field of oncology. Specific topics
covered include invasion and metastasis, miRNAs and metabolism, and
opportunities of miRNAs in therapeutics. Chapters on diseases
include content on disease-related pathophysiology, as well as
diagnostic, prognostic and predictive value. This book is an
essential reference for students entering the field, as well as
researchers and investigators.
Advances in Cancer Research provides invaluable information on the
exciting and fast-moving field of cancer research. Here, once
again, outstanding and original reviews are presented on a variety
of topics.
 |
Cancer
(Hardcover)
Susan E Pories, Marsha A Moses, Margaret M Lotz
|
R1,467
Discovery Miles 14 670
|
Ships in 10 - 15 working days
|
|
|
Once a certain death sentence and often a cause for shame,
cancer is now a treatable disease. "Cancer" provides a broad
introduction to this complex family of diseases, tracing the
fascinating history of scientific discoveries that led to today's
sophisticated treatments.
This extraordinary new volume, coauthored by three leaders in
cancer research and surgery at Harvard Medical School, uses
scientifically accurate yet accessible language to give readers a
firm grounding in such essential concepts as angiogenesis and the
genetics of cancer. In addition to information about types of
cancer, diagnosis, and treatment, "Cancer" places special emphasis
on new frontiers in research, psychological aspects of a cancer
diagnosis, and quality-of-life issues for those living with
disease. Useful features include a comprehensive glossary, a
timeline of milestones in cancer research, and an appendix for
students on how to pursue a career in science or medicine.
The traditional approach to cancer is that the patient must view
cancer as the enemy and engage in a war to vanquish that enemy. Ann
Wax, RN, argues that this approach is incorrect and invariably
leads to pain, self doubt, and depression. Instead, she argues that
one must find calm and inner-peace first, in order to promote
healing.
The interactions of cells with their surrounding extracellular
matrix (ECM) plays a pivotal role in driving normal cell behavior,
from development to tissue differentiation and function. At the
cellular level, organ homeostasis depends on a productive
communication between cells and ECM, which eventually leads to the
normal phenotypic repertoire that characterize each cell type in
the organism. A failure to establish these normal interactions and
to interpret the cues emanating from the ECM is one of the major
causes in abnormal development and the pathogenesis of multiple
diseases. To recognize and act upon the biophysical signals that
are generated by the cross talk between cells and ECM, the cells
developed specific receptors, among them a unique set of receptor
tyrosine kinases (RTKs), known as the Discoidin Domain Receptors
(DDRs). The DDRs are the only RTKs that specifically bind to and
are activated by collagen, a major protein component of the ECM.
Hence, the DDRs are part of the signaling networks that translate
information from the ECM, and thus they are key regulators of
cell-matrix interactions. Under physiological conditions, DDRs
control cell and tissue homeostasis by acting on collagen sensors;
transducing signals that regulate cell polarity, tissue
morphogenesis, cell differentiation, and collagen deposition. DDRs
play a key role in diseases that are characterized by dysfunction
of the stromal component, which lead to abnormal collagen
deposition and the resulting fibrotic response that disrupt normal
organ function in disease of the cardiovascular system, lungs and
kidneys, just to mention a few. In cancer, DDRs are hijacked by
tumor and stromal cells to disrupt normal cell-collagen
communication and initiate pro-oncogenic programs. Importantly,
several cancer types exhibit DDR mutations, which are thought to
alter receptor function, and contribute to cancer progression.
Therefore, the strong causative association between altered RTK
function and disease it is been translated today in the development
of specific tyrosine kinase inhibitors targeting DDRs for various
disease conditions. In spite of the accumulating evidence
highlighting the importance of DDRs in health and diseases, there
is still much to learn about these unique RTKs, as of today there
is a lack in the medical literature of a book dedicated solely to
DDRs. This is the first comprehensive volume dedicated to DDRs,
which will fill a gap in the field and serve those interested in
the scientific community to learn more about these important
receptors in health and disease.
Anti-angiogenic Drugs as Chemosensitizers in Cancer Therapy, Volume
19 focuses on the use of anti-angiogenic drugs as sensitizers of
tumor cells to the inhibitory activity of antitumor agents.
Conventional and novel anti-neoplastic agents (cytotoxic molecules,
hormones/antihormones, immunotherapies) are taken into
consideration, along with advances made in combination therapies.
The book encompasses examples of studies on the use of
antiangiogenic compounds-molecules that inhibit the growth of
vessels inside a tumor-together with antineoplastic drugs in order
to sensitize the resistant tumor to their cytotoxic effects, thus
reducing adverse side reactions and resistance and improving the
therapeutic response of cancer patients. In addition, the book
discusses clinical applications in various types of cancer, such as
colorectal, lung, breast, renal, genitourinary, skin and brain and
circulating tumors. It is a valuable resource for cancer
researchers, clinicians and members of the biomedical field who
wants to be up-to-date on the most recent and promising
developments in the field.
Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics
provides a review of the basic anatomy, physiology, biochemistry
and pathology of the eye with a focus drug therapy, drug delivery
and use of therapeutic medical miniature devices. An understanding
of the pharmacological actions of drugs acting on the eye requires
the student and health care practitioner to learn additional
principles in basic and clinical sciences that are unique to this
organ. As a sensory organ, the eye is relatively inaccessible to
the systemic circulation due to the blood-vitreous, blood-aqueous
and blood-retinal barriers. Consequently, the administration of
drugs for therapeutic effects in the eye necessitates an
understanding of physico-chemical properties of the molecules and
pharmacokinetic principles involved in the access to its site of
action via topical, intracameral and intravitreal administration.
This book includes information on the general principles of
pharmacokinetics and pharmacodynamics of drugs as it pertains to
the eye and in combating ocular disorders and diseases. Using a
disease-themed approach, the book discusses basic and clinical
pharmacological principles involved in the therapy of these
diseases including the ocular side effect of
systemically-administered drugs, drugs used in ophthalmic surgery
and miscellaneous agents, the therapeutic utility of biologics,
drug conjugates, combination products, gene and cellular therapy
are also covered. Handbook of Basic and Clinical Ocular
Pharmacology and Therapeutics is useful as a primary and secondary
source of reference for up-to-date information about the
pharmacological mechanisms of action, pharmacokinetics, side
effects, drug-drug interactions and therapeutic indications of
drugs for pharmacologists, pharmaceutical scientists, students in
the health care disciplines (nursing, pharmacy, optometry,
medical), and practitioners in optometry and ophthalmology.
Despite success with treatment when diagnosed early, breast cancer
is still one of the most fatal forms of cancer for women. Imaging
diagnosis is still one of the most efficient ways to detect early
breast changes with mammography among the most used techniques.
However, there are other techniques that have emerged as
alternatives or even complementary tests in the early detection of
breast lesions (e.g., breast thermography and electrical impedance
tomography). Artificial intelligence can be used to optimize image
diagnosis, increasing the reliability of the reports and supporting
professionals who do not have enough knowledge or experience to
make good diagnoses. Biomedical Computing for Breast Cancer
Detection and Diagnosis is a collection of research that presents a
review of the physiology and anatomy of the breast; the dynamics of
breast cancer; principles of pattern recognition, artificial neural
networks, and computer graphics; and the breast imaging techniques
and computational methods to support and optimize the diagnosis.
While highlighting topics including mammograms, thermographic
imaging, and intelligent systems, this book is ideally designed for
medical oncologists, surgeons, biomedical engineers, medical
imaging professionals, cancer researchers, academicians, and
students in medicine, biomedicine, biomedical engineering, and
computer science.
Currently, intensive effort is being directed toward the
identification of molecular targets that can provide approaches to
the development of novel therapeutic strategies in cancer
management. This book focuses on metastasis-associated genes,
metastasis promoter and suppressor genes, which relate specifically
to behavioral alterations of cancer cells in epithelial mesenchymal
transition, cancer stem cell maintenance and propagation, and to
the acquisition of invasive and metastasis faculty. The function of
these genes has implications for cell cycle regulation and cell
proliferation and so constitute an essential element in cancer
growth and dissemination. The emphasis in this book is on how
appropriate these genes are as molecular targets and how
practicable are the constituents of their signal transduction
systems as potential candidates and how accessible they are to
targeted therapy. Written in a straightforward and clear style with
background information supporting the new research, this book will
be useful for students and researchers in cancer therapies.
Identifies molecular targets and their accessibility for
therapeutic interventionProvides information on biological features
of tumor development and dissemination Background information
provided for each topic
In this issue of Radiologic Clinics, guest editor Dr. Hillary W.
Garner brings her considerable expertise to the topic of Imaging of
Bone and Soft Tissue Tumors and Mimickers. Top experts provide
timely articles on the imaging findings and other relevant clinical
information of frequently encountered benign and malignant tumors
of bone and soft tissue, in addition to separate reviews on common
and potentially confusing tumor mimics. In addition, orthopaedic
oncologists have contributed valuable perspectives on how they
incorporate imaging information into their patient care plans.
Contains 11 relevant, practice-oriented topics including bone
tumors: what the oncology team wants to know; bone tumors: imaging
features of common and rare benign entities; bone tumors: common
mimickers; soft tissue tumors: what the oncology team wants to
know; soft tissue tumors: common mimickers; bone and soft tissue
tumors: horizons in radiomics and artificial intelligence; and
more. Provides in-depth clinical reviews on imaging of bone and
soft tissue tumors and mimickers, offering actionable insights for
clinical practice. Presents the latest information on this timely,
focused topic under the leadership of experienced editors in the
field. Authors synthesize and distill the latest research and
practice guidelines to create clinically significant, topic-based
reviews.
|
|